"The pill" goes natural with potential new bestseller
This article was originally published in Scrip
Executive Summary
Teva’s NOMAC/E2 has become the first monophasic natural oestrogen contraceptive to be approved in the EU. Datamonitor believes that a perceived increased safety and a global launch will drive sales of the product, making it one the leading hormonal contraceptives brands with sales in excess of $350m. However, to maximize its potential Teva will hope that post marketing studies show improved safety over synthetic oestrogen contraceptives.